HYDERABAD, India — Akhil Ravi has been promoted to chief executive officer of Aurigene Pharmaceutical Services Ltd., a subsidiary of Dr. Reddy’s Laboratories Ltd.

Akhil Ravi

After joining Dr. Reddy’s in 2018 from McKinsey & Co., Ravi was head of strategy for services and active pharmaceutical ingredients, and headed sales of APIs in Europe. In addition, he had a brief stint as plant head.

“Akhil is very well prepared for this role. He was instrumental in growing our API business through product development and an improved service experience for our B2B customers through digital platforms. His strong background in customer service, sales, strategy, and management make him an ideal leader for Aurigene, and we look forward to his accomplishments in this new role,” says Deepak Sapra, CEO of API and services at Dr. Reddy’s and an Aurigene board member.

“Aurigene Pharmaceutical Services is a dynamic partner for global pharma companies,” says Ravi. “With its integrated services from clinical research up to commercial manufacturing for small and large molecules, it is able to significantly speed up the journey of an NCE/NBE (new chemical and biological entities) to the patient. I am very thrilled to join Aurigene and work with the team to serve innovative global pharma and biotech companies.”